Objective-Apolipoprotein A-V (apoA-V), a minor protein associated with lipoproteins, has a major effect on triacylglycerol (TG) metabolism. We investigated whether apoA-V complexed with phospholipid in the form of a reconstituted high-density lipoprotein (rHDL) has potential utility as a therapeutic agent for treatment of hypertriglyceridemia (HTG) when delivered intravenously. Methods and Results-Intravenous injection studies were performed in genetically engineered mouse models of severe HTG, including apoavϪ/Ϫ and gpihbp1Ϫ/Ϫ mice. Administration of apoA-V rHDL to hypertriglyceridemic apoavϪ/Ϫ mice resulted in a 60% reduction in plasma TG concentration after 4 hours. This decline can be attributed to enhanced catabolism/clearance of very-low-density lipoprotein (VLDL), where VLDL TG and cholesterol were reduced Ϸ60%.
E pidemiological studies have revealed that increased plasma triacylglycerol (TG) is an independent risk factor for coronary heart disease. 1, 2 Furthermore, hypertriglyceridemia (HTG) is a hallmark of the metabolic syndrome and is often accompanied by obesity and insulin resistance. 3 Given that the metabolic syndrome confers increased risk for development of both type 2 diabetes and cardiovascular disease, 4 maintenance of plasma TG homeostasis is highly desirable.
Following its discovery in 2001, 5, 6 apolipoprotein A-V (apoA-V) emerged as an important TG modulator. 7 In humans, APOAV is located in the APOAI/CIII/AIV/AV gene cluster on the long arm of chromosome 11. ApoA-V is expressed exclusively by liver tissue and, in plasma, is associated with high-density lipoprotein (HDL) and VLDL. 8, 9 Unlike other exchangeable apolipoproteins, the plasma concentration of apoA-V in humans (Ϸ250 ng/mL) 8 and mice (Ϸ24 ng/mL) 10 is extremely low. Despite this, the contribution of apoA-V to chylomicron and VLDL metabolism is readily appreciated from genetic engineering studies in mice. 5 ApoavϪ/Ϫ mice manifested a 4-fold increase in plasma TG, whereas the concentration in APOAV transgenic mice is 1/3 that in wild-type (WT) control littermates. Furthermore, studies in humans revealed an association between truncation mutations in apoA-V and severe HTG. [11] [12] [13] These data strongly suggest that apoA-V plays an important physiological role in plasma TG metabolism.
Previous in vivo studies demonstrated that HTG in apoA-V-deficient mice is attributable to decreased chylomicron and VLDL lipolysis and remnant removal. 14, 15 On the other hand, overexpression of apoA-V in mice via adenovirusmediated gene transfer led to a decrease in plasma TG. 16 -18 In vitro studies with apoA-V suggest that its TG-lowering activity may be explained by an ability to increase the efficiency of lipoprotein lipase (LPL)-mediated TG hydrolysis, 19 as well as an ability to increase remnant clearance by binding to members of the low-density lipoprotein (LDL) receptor family. 20, 21 Lipolysis is a key step in clearance of TG-rich lipoproteins that takes place on the luminal surface of capillaries of heart, skeletal muscle, and adipose tissues. LPL synthesized in muscle and adipocytes is translocated to capillary endothelial cells. Recent studies have shown that glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) binds the positively charged, heparinbinding domain of LPL 22,23 via its Ly6 domain and a negatively charged region in its amino terminus. In the absence of GPIHBP1, lipolysis is substantially diminished and plasma TG levels are markedly elevated. It has been postulated that GPIHBP1 serves as a platform that supports lipolytic activity. Interestingly, apoA-V also binds to GPIHBP1, most likely via a positively charged sequence motif located between residues 186 and 227. 23 ApoA-V also binds to heparin in vitro, and its presence on chylomicrons and VLDL confers heparin-binding capability. 19 Mutations in the positively charged sequence element of apoA-V result in reduced heparin and GPIHBP1 binding. 20, 23 Based on these findings, it is conceivable that apoA-V promotes attachment of TG-rich particles to endothelial cell surface heparan sulfate proteoglycans or GPIHBP1 and that such interactions enhance lipolysis.
In this report, we evaluate the potential utility of apoA-V as a TG-lowering therapeutic agent. Intravenous injection of apoA-V-containing reconstituted high-density lipoprotein (rHDL) significantly lowered plasma TG concentrations in apoavϪ/Ϫ mice yet had no effect in gpihbp1Ϫ/Ϫ mice. Mutation of positively charged amino acids in the heparinbinding region of apoA-V attenuated its TG-lowering capacity. Taken together, the data provide new mechanistic insight into the coordinate activities of LPL, GPIHBP1, and apoA-V in plasma TG homeostasis and suggest that intravenous administration of apoA-V may have therapeutic benefit in human subjects with severe HTG.
Methods

Materials
Primary antibodies included polyclonal goat anti-human apoA-V, 24 polyclonal goat anti-apoB (International Immunology), polyclonal goat anti-mouse apoA-I (Abcam), and polyclonal rabbit anti-mouse apoE (Biodesign International). Bis-Tris 4% to 20% NuPAGE gradient gels were from Invitrogen. Enzymatic assay kits for TG and cholesterol were from Wako Chemicals. Heparin was from Baxter. The fluorescent lipase substrate, 1,2-O-dilauryl-rac-glycero-3glutaric acid-(6Ј-methylresorufin) ester (DGGR), was from Sigma.
Animals
Previously described 9, 22 male mice (apoavϪ/Ϫ and gpihbp1Ϫ/Ϫ), aged 2 to 4 months, were used in these studies. Research was conducted in conformity with the Public Health Service Policy on the Humane Care and Use of Laboratory Animals and was approved by the animal use committees at Children's Hospital Oakland Research Institute and University of California, Los Angeles.
Preparation and Injection of apoA-V rHDL
Human WT apoA-V recombinant protein was prepared as described 24 ; the apoA-V mutant with changes in its positively charged sequence element (residues 186 to 227; Arg210Glu/Lys211Gln/ Lys215Gln/Lys217Glu) was previously described. 23 Because apoA-V is not soluble at pH 7.4, the protein was complexed with dimyristoylphosphatidyl choline (DMPC) for injection 24 ; briefly, DMPC vesicles were generated by extrusion through a 0.05-m membrane and subsequently complexed with recombinant apoA-V protein by sonication to form rHDL. Previous electron microscopy studies revealed that apoA-V rHDL consists of discoidal particles Ϸ14 nm diameter; by native polyacrylamide gel electrophoresis analysis, complexes were 12 to 17 nm in diameter. 24 In the present experiments, the size of apoA-V rHDL particles was confirmed on native gels. The mean protein:phospholipid (wt:wt) ratio in apoA-V rHDL was 1:6.3Ϯ0.6 (nϭ4). Controls used DMPC vesicles without protein. Mice were fasted 4 hours, and blood samples were obtained by submandibular vein bleeds before injection (tϭ0) and at 1, 2, and 4 hours postinjection. ApoA-V rHDL was injected by tail vein so as to achieve a plasma concentration of 12.5 g/mL (the average plasma concentration in APOAV transgenic mice 9 ). Mice were anesthetized with isoflurane. Plasma samples were rapidly separated and stored at Ϫ80°C.
Isolation of Plasma Lipoproteins
Lipoproteins from pooled plasma were separated by fast protein liquid chromatography (FPLC) with a Superose 6HR 10/30 column (Pharmacia LKB Biotechnology). Elution profiles were monitored at 280 nm, and 0.5-mL fractions were collected.
Measurement of Lipid Concentrations
Cholesterol and TG in plasma samples or FPLC fractions were determined by colorimetric assays (Wako).
Immunoblotting
Plasma (1 L) or concentrated FPLC fractions were electrophoresed on 4% to 20% Bis-Tris gradient gels. The size-separated proteins were transferred to polyvinylidene difluoride membranes, and immunoblots were processed as described. 24 In one experiment, clearance of apoA-V with time was determined by administrating 12.5 g/mL apoA-V rHDL and sampling plasma at 1 minute postinjection for baseline plasma apoA-V levels and at 1, 4, and 8 hours postinjection. Following electrophoresis on 4% to 20% gels and Western blotting, relative changes in plasma apoA-V compared with baseline were determined by densitometry using the NIH ImageJ program.
Measurement of Postheparin LPL Activity
ApoavϪ/Ϫ mice were injected via the tail vein with 50 L of heparin (50 U) 2 or 4 hours after injection with apoA-V rHDL or DMPC vesicles alone. Before and 15 minutes after heparin injection, blood samples were collected, and plasma was separated. LPL activities in the plasma samples were determined with a fluorometric assay as described. 25 Briefly, the lipase activity in the plasma sample was measured as the rate of fluorescence generated from hydrolysis of the lipase substrate DGGR. Two minutes after mixing plasma sample with DGGR, fluorescence intensity was monitored for 5 minutes, and lipase activity was calculated as relative fluorescence units generated per minute. LPL activity was determined by subtracting preheparin activity from postheparin activity. 26 
Results
Effect of Injected apoA-V on Plasma TG Concentration in apoav؊/؊ Mice
To evaluate the effect of parenteral administration of apoA-V on plasma TG concentration, apoA-V rHDL was injected into apoavϪ/Ϫ mice to achieve a plasma concentration of 12.5 g/mL, which is the average concentration of apoA-V in APOAV transgenic mice. 9 Compared with control mice injected with DMPC vesicles alone, apoA-V rHDL induced a 25% reduction in TG after 1 hour and a 60% reduction at 4 hours ( Figure 1A ). In controls, there was a slight reduction (Ϸ20%) in plasma TG concentration after 4 hours. Similar to changes in TG, apoA-V rHDL administration also decreased plasma cholesterol levels ( Figure 1B) . Consistent with the decline in TG, the total amount of apoB-100 protein in plasma also decreased after 4 hours along with apoA-V ( Figure 1C ). Unlike apoB-100 and apoA-V, there was no change in plasma levels of apoB-48.
In a separate experiment to determine changes in TG and apoA-V over a more extended period of time, mice (nϭ5) were injected with 12.5 g/mL apoA-V rHDL, and plasma was sampled after 1 minute to establish baseline values; subsequent plasma samples were obtained at 1, 4, and 8 hours postinjection. As noted in Supplemental Figure I (available online at http://atvb.ahajournals.org), TG continued to decline over the 8-hour period following apoA-V injection and was reduced approximately 87% at 8 hours. The DMPC control also showed a decline in TG by 8 hours but was significantly higher (PϽ0.01) than that of apoA-V treated mice. Using NIH ImageJ for evaluating relative intensity as a measure of apoA-V change over time, we found that 71.2Ϯ8.1%, 15.1Ϯ5.0%, and 3.0Ϯ0.7% apoA-V (Supplemental Figure II ) remained in the plasma at 1, 4, and 8 hours, respectively, suggesting that apoA-V is rapidly cleared from the plasma and parallels the reduction of TG.
The above data suggest that apoA-V injection can promote VLDL clearance in apoavϪ/Ϫ mice. To examine this issue further, plasma lipoprotein and apolipoprotein profiles were determined in apoavϪ/Ϫ mice before (time 0) and 4 hours after apoA-V rHDL injection. ApoA-V rHDL administration induced a major (Ϸ60%) reduction in VLDL TG and cholesterol, indicating that the decrease in plasma TG and cholesterol observed earlier reflects enhanced clearance of VLDL ( Figure  2A and 2B) . The fact that no concomitant increase in LDL or HDL cholesterol occurred indicates that remnant particles derived from VLDL do not accumulate in the plasma. The effect of apoA-V rHDL administration on the distribution of apolipoproteins among different lipoprotein fractions was then determined ( Figure 2C ). Similar to results obtained for plasma apoB-100, the amount of this protein in the VLDL fraction declined dramatically following apoA-V rHDL injection. By contrast, LDL apoB-100 was largely unaffected. After apoA-V rHDL injection, VLDL apoE levels decreased with a corresponding increase in HDL apoE content. VLDL apoA-I levels also decreased following apoA-V rHDL injection. Taken together, the data indicate VLDL clearance in apoavϪ/Ϫ mice increases following injection of apoA-V rHDL. The distribution of exogenously administered apoA-V among lipoproteins was determined at 1 and 4 hours postinjection ( Figure 2C ). Whereas the preponderance of apoA-V was found associated with VLDL at 1 hour, after 4 hours, VLDL was nearly devoid of apoA-V. These data support the premise that injected apoA-V exchanges onto VLDL particles, where it functions to facilitate their catabolism and clearance.
Dose-Response of apoA-V rHDL on TG-Lowering Activity
To determine the effect of apoA-V dose on its TG-lowering activity, apoavϪ/Ϫ mice were injected with different amounts of apoA-V rHDL to reach plasma concentrations of 6.25, 12.5, or 25 g/mL (time 0). Across this dose range, no differences in TG-lowering activity were observed, as shown in Supplemental Figure III . Thus, it may be concluded that the TG-lowering activity of apoA-V is saturated at plasma concentrations at or above 6.25 g/mL, consistent with the exceptionally low concentration of apoA-V in plasma under physiological conditions.
Effect of apoA-V rHDL on Postheparin LPL Activity
Previous studies indicate that postheparin LPL activity in apoavϪ/Ϫ mouse plasma is low compared with WT mice. 14 In addition, human carriers of an APOAV Gln139X mutation linked to severe HTG have reduced LPL activity. 11 To evaluate whether exogenously administered apoA-Vmediated TG lowering is related to increased postheparin LPL activity, apoavϪ/Ϫ mice were injected with apoA-V rHDL followed by heparin injection 2 or 4 hours later. LPL activity measurements revealed no significant difference between apoA-V rHDL-injected and DMPC vesicle-injected mice (Supplemental Figure IV) .
Site-Specific Mutations in apoA-V Attenuate Its TG-Lowering Activity
apoA-V contains a sequence element (amino acids 186 to 227) that lacks negatively charged residues and is enriched in positively charged amino acids. 19 We have previously shown that this region is involved in apoA-V binding to heparin, LDL receptor family members, and GPIHBP1. 19, 20, 23 Replacement of positively charged residues in this region of apoA-V with neutral or negatively charged amino acids (Mut-apoA-V) decreased its binding, in vitro, to heparin, LDL receptor-related protein and GPIHBP1. To examine effects on TG-lowering activity in vivo, Mut-apoA-V rHDL was injected into apoavϪ/Ϫ mice. Compared with WT apoA-V rHDL, the TG-lowering activity of Mut-apoA-V rHDL was attenuated by Ϸ50% ( Figure 3A) , consistent with defective binding to heparin or GPIHBP1. The decreased TG-lowering activity of Mut-apoA-V was not due to its inability to bind to VLDL because, as seen in Figure 3B , comparable amounts of WT and Mut-apoA-V associated with VLDL. Unlike WT apoA-V, however, a higher proportion of Mut-apoA-V remained associated with VLDL after 4 hours, consistent with delayed clearance of these particles. Taken together, the data indicate that the positively charged sequence element in apoA-V is required for optimal manifestation of its TG-lowering activity in vivo.
Effect of apoA-V rHDL Injection on Plasma TG Concentrations in gpihbp1؊/؊ Mice
Endothelial cell-bound GPIHBP1 plays a critical role in plasma TG homeostasis. 22 Indeed, gpihbp1Ϫ/Ϫ mice have extremely high plasma TG concentrations and diminished lipolysis. To determine whether parenteral administration of apoA-V rHDL can lower plasma TG in gpihbp1Ϫ/Ϫ mice, injection studies were performed. Following administration of apoA-V rHDL, no significant changes in plasma TG concentration were observed, compared with control littermates injected with DMPC vesicles alone ( Figure 4A ). It is noteworthy that although apoA-V was found primarily associated with VLDL as early as 1 hour after injection into gpihbp1Ϫ/Ϫ mice ( Figure 4B ), apoA-V levels did not decrease as a function of time, as was the case in apoavϪ/Ϫ mice (compare Figure 2C) . Taken together, the data suggest that GPIHBP1 is required for manifestation of the TGlowering activity of apoA-V in vivo, as well as clearance of this apolipoprotein from the circulation.
Discussion
Apolipoproteins have remarkable properties in that they function as ligands for cell-surface receptors, modulators of lipid metabolic enzymes, and acceptors of cell lipids (eg, cholesterol). Some apolipoproteins, such as apoA-I, have been shown to have potential as therapeutic agents. Recombinant human apoA-I was used for treatment of atheromas in patients with acute coronary syndromes. 27 In this case, a rare variant of human apoA-I, termed apoA-I Milano , was complexed with phospholipids, form- ing rHDL that was infused into patients; treatment resulted in significant reduction in atheroma burden.
Studies of apoA-V indicate that it is a potentially useful candidate for in vivo therapeutic applications. The severe HTG observed in human subjects harboring truncation mutations, 11, 13 as well as the strong correlation between coding and noncoding APOAV single-nucleotide polymorphisms and elevated plasma TG 28 -30 suggest that apoA-V therapy may be beneficial. ApoA-V variants in the general population are quite prevalent. Indeed, a recent analysis of multiple studies on TG elevation in cardiovascular disease suggest that the Ϫ1131TϾC allele, known to be correlated with TG concentrations, has an allele frequency of 8% 31 ; furthermore, Pullinger at al 30 showed that the c.553GϾT minor allele associated with elevated TG in unrelated Chinese Americans has a frequency of 4.5%. Like apoA-I, apoA-V readily forms rHDL that can be injected intravenously. In the current study, we demonstrate that injected apoA-V rHDL has the capacity to significantly reduce plasma TG concentrations in hypertriglyceridemic apoavϪ/Ϫ mice.
Although it is present in plasma at exceedingly low concentrations, apoA-V is an important modulator of plasma TG. 5, 7 apoavϪ/Ϫ mice exhibit elevated TG, whereas APOAV transgenic mice have reduced plasma TG. 5, 9 In addition to increased TG concentrations, diminished lipolysis of VLDL and a reduced rate of remnant uptake were observed in apoavϪ/Ϫ mice. 14 VLDL particles from apoavϪ/Ϫ mice are a poor substrate for LPL and have low binding to LDL receptor family members. In the current study, we show that parenteral delivery of apoA-V into apoavϪ/Ϫ mice lowered plasma TG concentrations and also reduced VLDL TG, cholesterol, and apoB-100 levels. These data indicate that apoA-V injection improves VLDL catabolism in apoavϪ/Ϫ mice.
The apoA-V dose used in the current study was based on the reported average plasma concentration in APOAV transgenic mice, whereas mouse apoA-V was reported to be 24 ng/mL in WT C57BL/6 mice. 10 Clearly, the very low levels of endogenous apoA-V in WT mice can efficiently clear newly formed TG-rich particles so that they do not accumulate in the plasma compartment. In the present study, 6.5 g/mL apoA-V was just as effective in lowering TG in apoa5Ϫ/Ϫ mice as the 12.5 g/mL dose. This suggests that apoA-V present in APOAV transgenic mice is functioning under saturation conditions and that concentrations lower than 6.25 g/mL are likely sufficient to lower TG. A major difference between WT and apoavϪ/Ϫ mice is that in the former case TG levels are low, whereas in the latter, TG is extremely elevated. It is likely that elevated plasma apoA-V in the form of exogenously delivered protein may be beneficial in clearance of TG in apoavϪ/Ϫ mice, where TG accumulation is exaggerated and endogenous apoA-V is lacking. In the latter case, there would be no replenishment of apoA-V as it is cleared from the circulation together with TG. In WT mice, on the other hand, where there is a constant production of apoA-V to offset clearance of the protein along with TG, the low level of apoA-V is sufficient to maintain low levels of TG.
GPIHBP1 is an endothelial cell protein that is required for the lipolytic processing of TG-rich lipoproteins in plasma. 22 In the absence of GPIHBP1, lipolysis of TG-rich particles is virtually abolished, leading to severe HTG in gpihbp1Ϫ/Ϫ mice. Injection of apoA-V failed to lower plasma TG levels in gpihbp1Ϫ/Ϫ mice, and apoA-V clearance was minimal, suggesting that these processes require interaction with GPIHBP1. To our knowledge, this is the first in vivo evidence suggesting that GPIHBP1 and apoA-V are functional partners in facilitating TG lipolysis.
In studies with Mut-apoA-V rHDL, we show that mutation of key positively charged amino acids in the putative heparinbinding domain of apoA-V attenuates the TG-lowering effect of apoA-V in apoavϪ/Ϫ mice. The clearance rate of the mutant protein was also slower than WT apoA-V. The decreased TG-lowering activity of the mutant was not due to a change in lipoprotein-binding ability because Mut-apoA-V, like WT apoA-V, was also found on VLDL at 1 and 4 hours postinjection. Taken together, the data suggest that the heparin-binding region of apoA-V plays an important role in its capacity to lower TG.
Previously, we proposed a mechanism whereby apoA-V could facilitate VLDL metabolism. 7 Briefly, under conditions of increased TG, apoA-V exchanges from HDL onto VLDL, which in turn interacts with heparan sulfate proteoglycans and GPIHBP1 on the surface of endothelial cells (where LPL also binds). Coordination among apoA-V, LPL, and GPIHBP1 results in accelerated TG hydrolysis. Our current in vivo studies support this mechanism by showing that (1) apoA-V was able to rapidly exchange from rHDL onto VLDL, (2) the interaction between apoA-V and GPIHBP1 is critical for its TG-lowering function, and (3) the positively charged heparin binding sequence element (residues 186 to 227) of apoA-V is required for this process. In addition, we also discovered that clearance of apoA-V from the circulation is minimal in the absence of GPIHBP1. Even though we cannot conclude that apoA-V is directly cleared through GPIHBP1, it is likely that the heparin-binding region of apoA-V is essential for its interaction with GPIHBP1, which in turn is essential for TG lipolysis.
In summary, we show that intravenous delivery of apoA-V has a profound TG-lowering effect in apoavϪ/Ϫ mice. Given that the effective dose is exceptionally low, parenteral administration of apoA-V may have potential therapeutic value for treating severe HTG in humans.
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